Fiche société
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Traitements, essais et publications liés.
Traitements11programmes
Essais5liés
Publications9liées
SourceDBlocale
Traitements
11| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| eletriptanTo assess the safety and efficacy of eletriptan for the treatment of migraine in subjects who had not been adequately treated with non-steroidal antiinflammatory drugs (NSAIDs) | Migraine | Phase 4 | Immunomodulation | Turkey (Türkiye) | À vérifier |
| Eletriptan 20 mgTo confirm the efficacy of three dose levels of oral eletriptan relative to placebo in relieving symptoms of acute migraine and to further explore the dose response relationship of eletriptan. | Migraine | Phase 3 | Traitement symptomatique | À vérifier | |
| Eletriptan 40 mgThe objective of this study was to compare the efficacy, toleration and safety of eletriptan 40mg and 80mg, with sumatriptan 25mg and 50mg, and placebo when given orally to subjects with an acute migraine. | Migraine | Phase 3 | À vérifier | À vérifier | |
| Eletriptan 80 mgThe objective of this study was to compare the efficacy, toleration and safety of eletriptan 40mg and 80mg, with sumatriptan 25mg and 50mg, and placebo when given orally to subjects with an acute migraine. | Migraine | Phase 3 | À vérifier | À vérifier | |
| Sumatriptan 100 mgThis proof-of-concept study compares side-by-side low-dose naltrexone and acetaminophen combination to sumatriptan in the acute treatment of migraine. | Migraine | Phase 3 | À vérifier | United States | À vérifier |
| Sumatriptan 25 mgThe objective of this study was to compare the efficacy, toleration and safety of eletriptan 40mg and 80mg, with sumatriptan 25mg and 50mg, and placebo when given orally to subjects with an acute migraine. | Migraine | Phase 3 | À vérifier | À vérifier | |
| Sumatriptan 50 mgThe objective of this study was to compare the efficacy, toleration and safety of eletriptan 40mg and 80mg, with sumatriptan 25mg and 50mg, and placebo when given orally to subjects with an acute migraine. | Migraine | Phase 3 | À vérifier | À vérifier | |
| eletriptanTo assess the safety and efficacy of eletriptan for the treatment of migraine in subjects who had not been adequately treated with non-steroidal antiinflammatory drugs (NSAIDs) | Migraine | Phase 4 | Immunomodulation | Turkey (Türkiye) | À vérifier |
| Eletriptan 40 mgThe objective of this study was to compare the efficacy, toleration and safety of eletriptan 40mg and 80mg, with sumatriptan 25mg and 50mg, and placebo when given orally to subjects with an acute migraine. | Migraine | Phase 3 | À vérifier | À vérifier | |
| Eletriptan 20 mgTo confirm the efficacy of three dose levels of oral eletriptan relative to placebo in relieving symptoms of acute migraine and to further explore the dose response relationship of eletriptan. | Migraine | Phase 3 | Traitement symptomatique | À vérifier | |
| Eletriptan 40 mgThe objective of this study was to compare the efficacy, toleration and safety of eletriptan 40mg and 80mg, with sumatriptan 25mg and 50mg, and placebo when given orally to subjects with an acute migraine. | Migraine | Phase 3 | À vérifier | À vérifier |
Essais cliniques
5| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Eletriptan 40 mg | Migraine | Phase 3 | NCT01986088 | Eletriptan vs Sumatriptan: A Double-blind, Placebo-controlled, Multiple Migraine Attack Study | COMPLETED |
| Eletriptan 20 mg | Migraine | Phase 3 | NCT01978496 | Efficacy, Safety, and Tolerability of Oral Eletriptan for Treatment of Acute Migraine | COMPLETED |
| Eletriptan 40 mg | Migraine | Phase 3 | NCT01986270 | Comparative Study of Oral Eletriptan (40mg and 80mg), Oral Sumatriptan (25mg and 50mg) and Placebo | COMPLETED |
| eletriptan | Migraine | Phase 4 | NCT00634985 | Safety and Efficacy of Eletriptan for the Treatment of Migraine in Subjects Unsuccessfully Treated With Nonsteroidal Anti-inflammatory Drugs | COMPLETED |
| pregabalin | Épilepsie | Phase 3 | NCT01262677 | Once-A-Day Pregabalin For Partial Seizures | COMPLETED |
Publications
9| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Sumatriptan 50 mg | Onset of action in placebo-controlled migraine attacks trials: A literature review and recommendation. | Cephalalgia : an international journal of headache | ||
| Sumatriptan 50 mg | Bergapten Attenuates Nitroglycerin-Induced Migraine Headaches through Inhibition of Oxidative Stress and Inflammatory Mediators. | ACS chemical neuroscience | ||
| Sumatriptan 50 mg | Rizatriptan as an Over-the-Counter Triptan in the Treatment of Migraine Attacks. | Pain and therapy | ||
| Eletriptan 20 mg | Economic analysis of triptan therapy for acute migraine: a Medicaid perspective. | Pharmacotherapy | ||
| Eletriptan 20 mg | Perimenstrual eletriptan prevents menstrual migraine: an open-label study. | Headache | ||
| Eletriptan 20 mg | Comparing the efficacy of eletriptan for migraine in women during menstrual and non-menstrual time periods: a pooled analysis of randomized controlled trials. | Headache | ||
| eletriptan | Novel Application of UHPLC-MS, HRMS, and 2D-NMR for Structural Elucidation of Eletriptan Hydrobromide and Its Novel Degradation Products. | Biomedical chromatography : BMC | ||
| eletriptan | Eletriptan HBr-loaded solid lipid nanoparticle-integrated microneedles: a targeted and minimally invasive approach for migraine management. | Journal of drug targeting | ||
| eletriptan | Chronic Migraine Resistance: A Case Report Highlights an Overlooked Factors in Family Medicine Clinics. | Healthcare (Basel, Switzerland) |